Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.41 |
| ▸ | TDP2 | O95551 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2780326 | 0.88 | MAPT (0.45) | MAPTHPGDALDH1A1POLBTSHR | |
| SCHEMBL2776728 | 0.84 | ALDH1A1 (0.46) | MAPTHPGDALDH1A1POLBTSHR | |
| SCHEMBL2775216 | 0.84 | TP53 (0.52) | MAPTHPGDALDH1A1POLBTSHR | |
| SCHEMBL2773536 | 0.83 | SCN9A (0.41) | ALDH1A1TDP2 | |
| SCHEMBL2774483 | 0.83 | TARBP2 (0.47) | MAPTHPGDALDH1A1POLBTSHR | |
| SCHEMBL2777901 | 0.83 | TARBP2 (0.47) | MAPTHPGDALDH1A1POLBALOX5 | |
| SCHEMBL2773587 | 0.81 | JAK2 (0.48) | MAPTALDH1A1CYP2C19TP53ALOX5 | |
| SCHEMBL2777575 | 0.79 | SCN9A (0.47) | MAPTHPGDALDH1A1POLBCYP2C19 | |
| SCHEMBL2777192 | 0.78 | SLC26A6 (0.46) | MAPTHPGDALDH1A1TP53 | |
| SCHEMBL2775619 | 0.78 | CYP2C19 (0.59) | MAPTPOLBTSHRCYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2227475-B1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | FIBROGEN INC (US) | 2014-02-19 | — | — | EP | disclosed |
| US-8269008-B2 | Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions | FIBROGEN, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100303928-A1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | FIBROGEN, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| EP-2227475-A1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | Fibrogen, Inc. (US) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009073669-A1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | FIBROGEN, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100303928-A1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | HIF1AN, HIF1A, EGLN2 | MAPT 3874/4885HPGD 23/4885ALDH1A1 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.